Form 4: Immunome Director Bienaime Acquires 7,000 Shares of IMNM
SEC Form 4 Filing
Jean Jacques Bienaime, a director at Immunome Inc., recently purchased 7,000 shares of the company's common stock at an average price of $13.944 per share.
Summary
- On August 16, 2024, Jean Jacques Bienaime, a director of Immunome Inc. (IMNM), acquired 7,000 shares of common stock.
- The purchase was made at a weighted average price of $13.944 per share, with individual prices ranging from $13.750 to $14.210.
- Following the transaction, Bienaime directly owns 16,615 shares of Immunome Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. Insider buying is generally viewed as a positive sign, but this single transaction is not overwhelmingly significant.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This purchase aligns with typical insider trading activity.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/15/2024 | Date of Earliest Transaction |
| 08/16/2024 | Date of stock purchase transaction |
| 08/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.